Feline Idiopathic Cystitis (FIC) - Detailed Treatment Protocol

Overview

1. Non-obstructive FIC - conservative and pharmacological management
2. Obstructive FIC (urethral obstruction, UO) - emergency treatment required

PART 1: NON-OBSTRUCTIVE FIC

First-Line: Multimodal Environmental Modification (MEMO)

Pharmacological Treatment - Non-Obstructive FIC

1. Analgesia (STRONGLY RECOMMENDED - first priority)

• Route: Transmucosal/sublingual (TM) or oral mucosal - the injectable formulation is given PO (absorbed via oral mucosa)
• Dose: 0.01-0.03 mg/kg (10-30 mcg/kg) PO/TM q6-12h
• Practical range from dvm360: 10-20 mcg/kg BID to QID depending on severity
• Duration: 3-5 days for acute episodes
• Notes: Excellent oral bioavailability in cats (~100% TM); well tolerated; good choice for home administration

• Dose: 5-10 mg/kg PO q8-12h (some protocols use up to 10 mg/kg q8h for pain)
• Also provides anxiolysis, which addresses the stress component
• Duration: 5-7 days for acute episodes; may be continued longer in recurrent cases

• Evidence: No studies have demonstrated benefit in FIC specifically
• If used: 0.1 mg/kg PO once on day 1, then 0.05 mg/kg PO q24h for 2-3 days
• Contraindications: dehydration, renal impairment, concurrent nephrotoxic drugs
• The 2025 iCatCare guidelines note NSAIDs (meloxicam, robenacoxib) have not been formally studied in non-obstructive FIC but can be used for their analgesic effect in well-hydrated cats with no renal impairment

2. Anxiolytics / Antispasmodics (acute episode)

• Dose: 2.5 mg/cat PO BID to TID (oral)
• Used alongside buprenorphine for acute episodes with significant discomfort
• Helpful particularly when stress/anxiety is a prominent trigger

• Dose: 7.5 mg/cat PO q48h (use cautiously - limited evidence)
• May reduce severity and frequency of urge incontinence/dysuria
• Symptomatic only; does not affect recovery rate

Pharmacological Treatment - Recurrent / Chronic FIC

3. Tricyclic Antidepressants (TCAs)

• Mechanism: Anxiolytic, analgesic (central), anticholinergic (reduces bladder spasm), antihistamine properties
• Dose: 5-10 mg/cat PO q24h (given at owner's bedtime to minimize sedation)
• Evidence: One non-controlled study showed 60% resolution of severe recurrent FIC over 1 year at 10 mg/cat/day
• Important caveats from 2025 evidence:
  • Two recent studies found no benefit for acute bouts; TCAs are for prevention only
  • Abrupt cessation after 7 days worsened signs - must taper gradually
  • Taper dose gradually after at least 3 months of use; stop when possible
• Monitoring: CBC (rare bone marrow effects), cardiac function; avoid in cats with heart disease

• Dose: 0.5 mg/kg PO q24h
• Similar mechanism to amitriptyline; may be considered as alternative

4. SSRIs / SNRIs

• Dose: 1 mg/kg PO q24h (or 2-5 mg/cat q24h)
• Evidence: Shown to decrease urine spraying (stress-related elimination); useful in cases where anxiety/compulsive behavior is prominent
• The 2025 iCatCare guidelines confirm usefulness; may be better tolerated than TCAs in some cats
• Allow 4-6 weeks for full effect

PART 2: OBSTRUCTIVE FIC (Urethral Obstruction - EMERGENCY)

Step 1: Stabilization

• IV catheter placement; correct metabolic abnormalities (hyperkalemia, acidosis)
• IV fluid therapy: Lactated Ringer's solution (avoid potassium-containing fluids until hyperkalemia resolved)
• ECG monitoring for arrhythmias secondary to hyperkalemia

Step 2: Sedation/Analgesia for Unblocking

• Butorphanol: 0.2-0.4 mg/kg IM/IV + Dexmedetomidine: 5-20 mcg/kg IM (commonly used combination for short-term sedation)
• OR Ketamine: 1-5 mg/kg IV/IM combined with dexmedetomidine
• Pass urinary catheter (3.5 Fr tom-cat catheter or flexible red rubber catheter); flush bladder with sterile saline

• Acepromazine: 0.25 mg/cat IM OR 2.5 mg/cat PO q8h
• Buprenorphine: 0.075 mg/cat IM q8h
• Medetomidine: 0.1 mg/cat IM q24h (added after 24h)
• Massage distal penis to dislodge obstruction
• Subcutaneous fluids + decompressive cystocentesis
• Darkened, low-traffic environment
• Result: Spontaneous urination in >70% of cases within 72h
• Note: Only for suspected spasm - will fail if physical obstruction (urolithiasis) is present

Step 3: Post-Unblocking Management

• Dose: 0.25-0.5 mg/cat PO q12-24h (some sources: 0.5 mg/cat q12h for 2-4 weeks)
• Mechanism: Selective alpha-1 adrenergic antagonist; relaxes urethral smooth muscle
• Evidence: Retrospective study showed significantly lower risk of recurrent UO vs phenoxybenzamine
• Duration: 1-4 weeks post-catheter removal, then reassess

• Dose: 2.5 mg/cat PO q12h
• Higher side effect profile; less selective than prazosin

• Continue IV fluids at maintenance to 1.5x maintenance for 12-24h after catheter placement
• Indwelling urinary catheter (closed collection system) typically left in place 12-48h

• Buprenorphine: 0.01-0.02 mg/kg TM q6-8h for 3-5 days
• Gabapentin: 5-10 mg/kg PO q8-12h (also reduces anxiety/stress)

PART 3: DRUGS WITH NO PROVEN BENEFIT (Avoid Routine Use)

PART 4: EMERGING / INVESTIGATIONAL OPTIONS

• Frunevetmab (anti-nerve growth factor monoclonal antibody) - not yet studied in non-obstructive FIC as of 2025 iCatCare guidelines; theoretically relevant given NGF's role in pain sensitization
• Pregabalin - not yet formally studied in FIC; may have theoretical benefit similar to gabapentin

Quick Reference Summary Table

Key Clinical Pearls

1. Antibiotics are NOT indicated for FIC - this is a sterile condition; use only if culture confirms UTI
2. MEMO should be attempted before or alongside any drug therapy - environmental modification is the most evidence-based long-term intervention
3. Amitriptyline is for prevention only, not acute treatment; abrupt discontinuation worsens disease
4. Corticosteroids are contraindicated - no benefit and increase infection risk
5. Prazosin is preferred over phenoxybenzamine for post-UO urethral relaxation
6. Most non-obstructed FIC resolves in 5-7 days with or without treatment; goal is comfort
7. Recurrent obstruction risk is highest in the first 6 months - prazosin + environmental modification are key preventive strategies
8. The 2025 iCatCare consensus guidelines explicitly state the condition is primarily stress-neuroendocrine, not purely inflammatory, so stress management is physiologically fundamental, not just supportive

• 2025 iCatCare Consensus Guidelines (Taylor S et al., J Feline Med Surg, 2025) [PMID: 39935081]
• Macleod B et al., "Understanding the current evidence base for management of recurrent FIC: a systematic review," N Z Vet J, 2025 [PMID: 40147044]
• dvm360 FIC Proceedings - Buffington CA
• WSAVA 2017 - FIC: Where Are We Now?